The DOI matches its Crossref record; 97 of the 97 references it cites were found in a registry or an index.
Aptamers in the Therapeutics and Diagnostics Pipelines
Open accessAbstract
Aptamers are short single-stranded DNA or RNA oligonucleotides that can selectively bind to small molecular ligands or protein targets with high affinity and specificity, by acquiring unique three-dimensional structures.Aptamers have the advantage of being highly specific, relatively small in size, non-immunogenic and can be easily stabilized by chemical modifications, thus allowing expansion of their diagnostic and therapeutic potential.Since the invention of aptamers in the early 1990s, great efforts have been made to make them clinically relevant for diseases like macular degeneration, cancer, thrombosis and inflammatory diseases.Furthermore, owing to the aforementioned advantages and unique adaptability of aptamers to point-of-care platforms, aptamer technology has created a stable niche in the field of in vitro diagnostics by enhancing the speed and accuracy of diagnoses.The aim of this review is to give an overview on aptamers, highlight the inherent therapeutic and diagnostic opportunities and challenges associated with them and present various aptamers that have reached therapeutic clinical trials, diagnostic markets or that have immediate translational potential for therapeutics and diagnostics applications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,405
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,687
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Aptamers as targeted therapeutics: current potential and challenges
Zhou, J., & Rossi, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.199 · Cited by 2,221
Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544
Aptamers evolved from live cells as effective molecular probes for cancer study
Shangguan, D., Li, Y., Tang, Z., Cao, Z. C., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. J., & Tan, W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602615103 · Cited by 1,516
Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer
Bates, P. J., Laber, D. A., Miller, D. M., Thomas, S. D., & Trent, J. O. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.01.004 · Cited by 874
Ruckman, J., Green, L. S., Beeson, J., Waugh, S., Gillette, W. L., Henninger, D. D., Claesson-Welsh, L., & Janjic, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.32.20556 · Cited by 744
Current approaches in SELEX: An update to aptamer selection technology
Darmostuk, M., Rimpelova, S., Gbelcova, H., & Ruml, T. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.02.008 · Cited by 702
Cited by
The Limitless Future of RNA Therapeutics
Damase, T. R., Sukhovershin, R., Boada, C., Taraballi, F., Pettigrew, R. I., & Cooke, J. P. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.628137 · Cited by 544
The Era of Digital Health: A Review of Portable and Wearable Affinity Biosensors
Tu, J., Torrente‐Rodríguez, R. M., Wang, M., & Gao, W. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201906713 · Cited by 357
Therapeutic applications of AS1411 aptamer, an update review
Yazdian-Robati, R., Bayat, P., Oroojalian, F., Zargari, M., Ramezani, M., Taghdisi, S. M., & Abnous, K. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.11.118 · Cited by 288
The impact of protein corona on the biological behavior of targeting nanomedicines
Farshbaf, M., Valizadeh, H., Panahi, Y., Fatahi, Y., Chen, M., Zarebkohan, A., & Gao, H. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121458 · Cited by 95
RNA-based therapeutics to treat human fungal infections
Bruch, A., Kelani, A. A., & Blango, M. G. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.09.007 · Cited by 39
“Only one aptamer drug has been approved for therapeutic use – for the treatment of age-related macular degeneration (Pegaptanib); however, numerous clinical trials are now underway [14,32].”
Background
Metadata
- Authors
- Kaur, H., Bruno, J. G., Kumar, A., & Sharma, T. K.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2018
- Volume
- 8
- Issue
- 15
- Pages
- 4016-4032
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2884141826
- Cited by
- 366
- References
- 97
- FWCI
- 14.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aptamers in the Therapeutics and Diagnostics Pipelines. https://app.cochat.ai/papers/10.7150/thno.25958
- The paper
- Kaur, H., Bruno, J. G., Kumar, A., & Sharma, T. K. (2018). Aptamers in the Therapeutics and Diagnostics Pipelines. Theranostics. https://doi.org/10.7150/thno.25958
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
